ZVRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zevra Therapeutics Inc (ZVRA) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has potential upside catalysts and positive analyst ratings, the insider selling trend, declining net income, and lack of significant AI or SwingMax trading signals suggest a cautious approach. The investor may consider monitoring the stock for better entry points or further positive developments.
The MACD is positive and expanding (0.084), suggesting bullish momentum. RSI is at 77.62, indicating the stock is nearing overbought territory. Moving averages are converging, showing no clear trend. The stock is trading near its R1 resistance level of 10.405, with further resistance at 10.75.
Analysts have a Buy rating with a price target of $23, indicating significant upside potential. Miplyffa's launch is performing well, and future catalysts include potential EU approval and patent term extensions.
Insiders are selling heavily, with an 809.12% increase in selling activity over the last month. Net income and EPS have significantly declined YoY, despite revenue growth. No recent news or congress trading data to provide additional confidence.
In Q4 2025, revenue increased by 183.36% YoY to $34.13M, and gross margin improved to 94.62%. However, net income dropped by -133.10% YoY to $11.83M, and EPS fell by -129.85% YoY to 0.2.
BTIG and Guggenheim have Buy ratings with a $23 price target. Analysts highlight Miplyffa's strong performance and future growth potential, but current valuation reflects conservative adoption.
